India has been in a state of financial crisis for a while now, and the country is also facing a massive cash crunch.
But that has not deterred investors from buying Exela’s stock, which is gaining momentum and has gained over 100% in value over the past year.
The stock has gained a lot in recent months, thanks to several big news stories, including that it had been granted a patent for a 3D ultrasound machine.
But its market cap has not kept pace with the technology’s rise.
The startup has also become a big player in the artificial intelligence space, which has made it one of the biggest names in AI, with $1.5 billion in funding.
So, the stock is in a great spot right now.
However, there is one big problem for Exela investors: Its shares are worth less than they were last year.
So even though it is growing, its shares are still trading at a loss.
Read moreWhat is Exela and how did it gain so much value?
What is a 3d ultrasound?
In the near future, a 3-D ultrasound will be used to help doctors and surgeons visualize and treat the tissues of the body.
An ultrasound machine uses a laser to produce a 3×3 grid of images in real time.
A surgeon could then use the 3D images to determine the exact location and size of various organs.
This is a big deal, and it has huge potential for treating many medical conditions.
But it has also been used for more than just medical purposes.
In the past, a surgeon would use a 3rd-generation ultrasound scanner to look at the anatomy of a patient’s tumour and then use that to diagnose and treat that tumour.
Now, that same 3D image will be able to be used in real-time to make a 3 dimensional picture of a specific organ.
This will allow doctors to see exactly how a particular organ is connected with the body and where it needs to be removed to treat it.
In other words, doctors will be much better equipped to deal with tumours and the associated complications.
In the past few years, Exela has been working on a 3 D ultrasound scanner, which will be one of its key innovations.
This technology is called a bio-receiver, and its main purpose is to help diagnose and manage diseases.
A bio-reciever uses a 3.5D camera to capture a 3X3 grid and upload it into a computer.
This image is then used to create a 3DS view of a tumour, which shows its location, size and location of organs.
This is then compared with other images of the tumour from other labs.
A medical doctor can then analyse the image and determine if the tumours are tumours, tumors or other different diagnoses.
This technology has also helped Exela in developing its own 3D scan.
This means it will be more capable of providing 3D scans to the hospitals in India.
The company’s CEO, Gopal Gopalan, told BusinessLine that the 3-dimensional scan will help doctors to better understand the health of patients and make sure that the best treatments are available for them.
“This is one of our top technologies and we believe this will give us the best chance of solving the huge number of healthcare problems that our country faces,” Gopalin said.
The technology is not without its problems.
There are several hurdles before doctors can use this technology to scan a patient.
For instance, it needs a 3 axis scanner and a high resolution 3D camera.
For this, doctors need to have an understanding of the anatomy and size, and also have the 3 D scanner in their hospitals.
These challenges are not insurmountable, however, because of the company’s research into 3D imaging, which makes it much cheaper than a traditional MRI.
The 3D scanner will also be needed to provide a 3 point scan, which means that the scans will be three dimensional.
This will be an important step in getting more accurate 3D information about the body, which could potentially make it a much more accurate and accurate health tool.
The startup has a lot of potential.
The company is still in its infancy, but it has some huge plans in the near term.
The CEO also said that Exela hopes to get funding from some investors.
The founders are hoping to launch their product next year, and there are plans to make it available to hospitals across the country.
But if Exela does not get a good valuation in the coming years, it is still very much worth investing in.